Osteoporosis Treatment: Medications, Lifestyle & Emerging Therapies
Comprehensive Osteoporosis Management
1. Pharmacotherapy (Fracture Risk–Guided)
| Class | Agents | Mechanism | Indication |
|---|---|---|---|
| Bisphosphonates | Alendronate, risedronate, ibandronate, zoledronic acid | Antiresorptive (inhibit osteoclast) | First-line; oral/IV |
| Denosumab | Prolia (60 mg SC q6mo) | Anti-RANKL (antiresorptive) | High risk, renal impairment, BP intolerant |
| Anabolics | Teriparatide, abaloparatide (daily SC × 2 yr max) | Stimulate osteoblast → new bone | Very high risk, fractures on antiresorptives |
| Romosozumab | Evenity (210 mg SC qmo × 1 yr) | Anti-sclerostin (anabolic + antiresorptive) | Very high risk; CV caution |
| SERM | Raloxifene | Estrogen agonist on bone | Postmenopausal; also ↓breast Ca risk |
| HRT | Estrogen ± progestin | Antiresorptive | Young postmenopausal with symptoms |
2. Lifestyle Foundation
- Calcium 1200 mg/day (diet + supplement)
- Vitamin D 2000–4000 IU/day (target 30–50 ng/mL)
- Weight-bearing + resistance exercise 3–4×/wk
- Fall prevention: balance training, home safety, vision check
- Smoking cessation, alcohol ≤2 drinks/day
3. Monitoring
- DEXA q1–2 yr (spine/hip)
- Bone turnover markers (CTX, P1NP) for adherence/response
- Drug holiday assessment after 3–5 yr (bisphosphonates)
Treatment individualized by FRAX score, fracture history, comorbidities, patient preference.
Osteoporosis - Related Articles
- Soy and Osteoporosis Prevention: A Natural Approach
- Osteoporosis Medications: A Comprehensive Guide for Patients
- Osteoporosis in Women: Risk, Symptoms & Prevention
- Fosamax (Alendronate): Side Effects, Uses & Safety
- Safe and Effective Osteoporosis Medications: A Comprehensive Guide
- Understanding Osteoporosis: Bone Loss, Density & Risk
- Osteoporosis Treatment for Women: Effective Strategies & Prevention
